Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 15, 2024 08:00 ET
|
Phathom Pharmaceuticals
First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD)...
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
May 15, 2024 06:59 ET
|
atai Life Sciences
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
May 14, 2024 16:15 ET
|
Lumos Pharma, Inc.
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201...
Global Iron Drugs Strategic Business Report 2024: Market to Reach $11 Billion by 2030 with Oral Segment to Account for $6.7 Billion
May 14, 2024 10:09 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Iron Drugs Market to Reach $11 Billion...
Design 1st and Swabbot Elevate Industrial Cleaning with Collaborative Robot Solution Engineered for Precision, Safety, and Efficiency
May 14, 2024 08:00 ET
|
Design 1st
OTTAWA, May 14, 2024 (GLOBE NEWSWIRE) -- Design 1st, one of the most prolific full-service product design-engineering firms across North America, in partnership with Swabbot, announced today the...
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
May 14, 2024 05:53 ET
|
ALLIANCE PROMOTION MICROBIOTE
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai...
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
May 14, 2024 05:53 ET
|
ALLIANCE PROMOTION MICROBIOTE
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 -...
MRSA Drugs Global Strategic Research Report 2024: Market to Reach $1.6 Billion by 2030 - Glycopeptides & Lipoglycopeptides to Account for $660 Million
May 13, 2024 09:55 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "MRSA Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global MRSA Drugs Market to Reach $1.6...
Lifestyle Drugs Global Strategic Business Report 2024
May 13, 2024 09:11 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Lifestyle Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Lifestyle Drugs Market to Reach...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
May 09, 2024 14:51 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first...